A phase 1, first-in-human study of trail receptor agonist abbv-621 in subjects with previously-treated solid tumors and hematologic malignancies
2016-003887-37Tumores sólidos y neoplasias malignas hematológicasFundación Jiménez DíazInvestigador: Moreno García Víctor
